| Literature DB >> 29050278 |
Chenhua Sun1, Qi Yuan2, Dongdong Wu1, Xiaohu Meng1, Baolin Wang1,3.
Abstract
Gastric cancer (GC) is a common malignant neoplasm of gastrointestinal tract. We chose gene expression profile of GSE54129 from GEO database aiming to find key genes during the occurrence and development of GC. 132 samples, including 111 cancer and 21 normal gastric mucosa epitheliums, were included in this analysis. Differentially expressed genes (DEGs) between GC patients and health people were picked out using GEO2R tool, then we performed gene ontology (GO) analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis using The Database for Annotation, Visualization and Integrated Discovery (DAVID). Moreover, Cytoscape with Search Tool for the Retrieval of Interacting Genes (STRING) and Molecular Complex Detection (MCODE) plug-in was utilized to visualize protein-protein interaction (PPI) of these DEGs. There were 971 DEGs, including 468 up-regulated genes enriched in focal adhesion, ECM-receptor interaction and PI3K-Akt signaling pathway, while 503 down-regulated genes enriched in metabolism of xenbiotics and drug by cytochrome P450, chemical carcinogenesis, retinol metabolism and gastric acid secretion. Three important modules were detected from PPI network using MCODE software. Besides, Fifteen hub genes with high degree of connectivity were selected, including BGN, MMP2, COL1A1, and FN1. Moreover, the Kaplan-Meier analysis for overall survival and correlation analysis were applied among those genes. In conclusion, this bioinformatics analysis demonstrated that DEGs and hub genes, such as BGN, might promote the development of gastric cancer, especially in tumor metastasis. In addition, it could be used as a new biomarker for diagnosis and to guide the combination medicine of gastric cancer.Entities:
Keywords: bioinformatics analysis; combination medicine; diagnosis; gastric cancer; protein-protein interaction
Year: 2017 PMID: 29050278 PMCID: PMC5642553 DOI: 10.18632/oncotarget.20082
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Top 15 hub genes with higher degree of connectivity
| Gene | Degree of connectivity | Adjusted |
|---|---|---|
| CTNNB1 | 24 | 3.13E-22 |
| FN1 | 16 | 5.13E-21 |
| FYN | 15 | 1.98E-34 |
| MMP9 | 14 | 2.28E-09 |
| COL1A1 | 11 | 1.47E-33 |
| ITCH | 11 | 1.62E-30 |
| TGFB1 | 10 | 6.43E-42 |
| THBS1 | 9 | 1.03E-22 |
| MMP2 | 9 | 3.07E-18 |
| ACTA2 | 8 | 1.67E-08 |
| ITGA5 | 8 | 5.44E-20 |
| BMP2 | 8 | 5.61E-24 |
| BGN | 7 | 1.50E-28 |
| HSPA4 | 7 | 7.44E-32 |
| PIK3R1 | 7 | 2.29E-37 |
Gene ontology analysis of differentially expressed genes associated with gastric cancer
| Expression | Category | Term | Count | % | FDR | |
|---|---|---|---|---|---|---|
| Up-regulated | GOTERM_BP_FAT | GO:0001944∼vasculature development | 67 | 19.65 | 7.50E-31 | 1.43E-27 |
| GOTERM_BP_FAT | GO:0001568∼blood vessel development | 62 | 18.18 | 5.72E-28 | 1.09E-24 | |
| GOTERM_BP_FAT | GO:0048514∼blood vessel morphogenesis | 56 | 16.42 | 2.00E-26 | 3.82E-23 | |
| GOTERM_BP_FAT | GO:0072358∼cardiovascular system development | 75 | 21.99 | 1.28E-25 | 2.43E-22 | |
| GOTERM_BP_FAT | GO:0072359∼circulatory system development | 75 | 21.99 | 1.28E-25 | 2.43E-22 | |
| GOTERM_MF_FAT | GO:0005539∼glycosaminoglycan binding | 28 | 8.21 | 3.99E-15 | 6.14E-12 | |
| GOTERM_MF_FAT | GO:0008201∼heparin binding | 23 | 6.74 | 4.66E-13 | 7.16E-10 | |
| GOTERM_MF_FAT | GO:1901681∼sulfur compound binding | 26 | 7.62 | 3.41E-12 | 5.23E-09 | |
| GOTERM_MF_FAT | GO:0005102∼receptor binding | 64 | 18.77 | 6.71E-10 | 1.03E-06 | |
| GOTERM_MF_FAT | GO:0032403∼protein complex binding | 42 | 12.32 | 2.71E-09 | 4.17E-06 | |
| GOTERM_CC_FAT | GO:0031012∼extracellular matrix | 66 | 19.35 | 8.53E-32 | 1.23E-28 | |
| GOTERM_CC_FAT | GO:0005578∼proteinaceous extracellular matrix | 52 | 15.25 | 7.99E-28 | 1.16E-24 | |
| GOTERM_CC_FAT | GO:0044421∼extracellular region part | 159 | 46.63 | 7.12E-21 | 1.03E-17 | |
| GOTERM_CC_FAT | GO:0005615∼extracellular space | 87 | 25.51 | 9.70E-20 | 1.40E-16 | |
| GOTERM_CC_FAT | GO:0005576∼extracellular region | 171 | 50.15 | 4.15E-18 | 6.00E-15 | |
| Down-regulated | GOTERM_BP_FAT | GO:0030855∼epithelial cell differentiation | 42 | 10.85 | 2.99E-13 | 5.61E-10 |
| GOTERM_BP_FAT | GO:0007586∼digestion | 21 | 5.43 | 5.83E-11 | 1.10E-07 | |
| GOTERM_BP_FAT | GO:0060429∼epithelium development | 49 | 12.66 | 3.66E-08 | 6.88E-05 | |
| GOTERM_BP_FAT | GO:0006805∼xenobiotic metabolic process | 14 | 3.62 | 5.49E-08 | 1.03E-04 | |
| GOTERM_BP_FAT | GO:0006629∼lipid metabolic process | 56 | 14.47 | 7.06E-08 | 1.33E-04 | |
| GOTERM_MF_FAT | GO:0016614∼oxidoreductase activity, acting on CH-OH group of donors | 22 | 5.68 | 2.20E-13 | 3.43E-10 | |
| GOTERM_MF_FAT | GO:0016616∼oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 17 | 4.39 | 9.66E-10 | 1.51E-06 | |
| GOTERM_MF_FAT | GO:0004745∼retinol dehydrogenase activity | 8 | 2.07 | 2.60E-08 | 4.05E-05 | |
| GOTERM_MF_FAT | GO:0004033∼aldo-keto reductase (NADP) activity | 7 | 1.81 | 1.08E-05 | 0.016818 | |
| GOTERM_MF_FAT | GO:0016709∼oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen | 7 | 1.81 | 1.71E-04 | 0.266413 | |
| GOTERM_CC_FAT | GO:0044421∼extracellular region part | 124 | 32.04 | 5.03E-08 | 7.04E-05 | |
| GOTERM_CC_FAT | GO:0005576∼extracellular region | 140 | 36.18 | 1.05E-07 | 1.47E-04 | |
| GOTERM_CC_FAT | GO:0045177∼apical part of cell | 26 | 6.72 | 1.38E-07 | 1.93E-04 | |
| GOTERM_CC_FAT | GO:0070062∼extracellular exosome | 92 | 23.77 | 3.26E-06 | 0.004567 | |
| GOTERM_CC_FAT | GO:1903561∼extracellular vesicle | 92 | 23.77 | 4.04E-06 | 0.005651 |
GO: Gene Ontology; FDR: False Discovery Rate.
KEGG pathway analysis of differentially expressed genes associated with gastric cancer
| Category | Term | Count | % | Genes | FDR | |
|---|---|---|---|---|---|---|
| Up-regulated DEGs | hsa04510:Focal adhesion | 25 | 7.3 | 5.06E-11 | TLN1, TNC, MYL9, COL6A3, COL6A2, COL6A1, ZYX, THBS1, COL11A1, THBS2, PIK3R1, SPP1, THBS4, FN1, COL4A2, COL4A1, IGF1, FLNA, VEGFC, FYN, ITGA5, ITGA7, COL1A2, COL1A1, MYLK | 6.32E-08 |
| hsa04512:ECM-receptor interaction | 16 | 4.7 | 1.13E-09 | COL4A2, COL4A1, TNC, ITGA5, ITGA7, COL6A3, COL6A2, COL1A2, COL6A1, COL1A1, THBS1, THBS2, COL11A1, SPP1, THBS4, FN1 | 1.42E-06 | |
| hsa04151:PI3K-Akt signaling pathway | 25 | 7.3 | 1.34E-06 | MCL1, OSMR, TNC, BCL2L1, IL7R, COL6A3, COL6A2, COL6A1, IL2RG, THBS1, COL11A1, THBS2, PIK3R1, SPP1, THBS4, FN1, COL4A2, COL4A1, IGF1, YWHAE, VEGFC, ITGA5, ITGA7, COL1A2, COL1A1 | 0.001667 | |
| hsa04974:Protein digestion and absorption | 12 | 3.5 | 5.64E-06 | COL4A2, COL14A1, COL4A1, COL6A3, ELN, COL1A2, COL6A2, COL12A1, COL6A1, COL1A1, COL11A1, COL10A1 | 0.007038 | |
| hsa04270:Vascular smooth muscle contraction | 12 | 3.5 | 9.93E-05 | EDNRA, GNA13, ACTG2, ACTA2, CALD1, PLA2G2A, GUCY1A3, GUCY1B3, CALCRL, MYLK, KCNMB1, MYL9 | 0.123856 | |
| Down-regulated DEGs | hsa00980:Metabolism of xenobiotics by cytochrome P450 | 12 | 3.1 | 2.08E-07 | GSTA1, CYP3A4, CYP3A5, CBR1, CYP2C9, ADH1C, AKR7A3, ADH1A, ADH7, UGT2B15, AKR1C1, ALDH3A1 | 2.56E-04 |
| hsa05204:Chemical carcinogenesis | 12 | 3.1 | 4.70E-07 | GSTA1, CYP3A4, CYP3A5, CBR1, CYP2C19, CYP2C9, CYP2C18, ADH1C, ADH1A, ADH7, UGT2B15, ALDH3A1 | 5.78E-04 | |
| hsa00830:Retinol metabolism | 11 | 2.8 | 5.47E-07 | CYP3A4, RDH12, CYP3A5, CYP2C9, CYP2C18, ADH1C, DHRS9, SDR16C5, ADH1A, ADH7, UGT2B15 | 6.72E-04 | |
| hsa00982:Drug metabolism - cytochrome P450 | 11 | 2.8 | 8.44E-07 | GSTA1, CYP3A4, FMO5, CYP3A5, CYP2C19, CYP2C9, ADH1C, ADH1A, ADH7, UGT2B15, ALDH3A1 | 0.001037 | |
| hsa04971:Gastric acid secretion | 11 | 2.8 | 1.66E-06 | KCNJ16, KCNJ15, ATP4A, GNAQ, ATP4B, SLC26A7, KCNE2, GAST, CA2, SST, KCNK10 | 0.002035 |
KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: False Discovery Rate.
Figure 3Prognostic value of four genes (BGN (A), MMP2 (B), COL1A1 (C), FN1 (D)) in gastric cancer patients. The desired Affymetrix IDs are valid: 201261_x_at(BGN), 201069_at (MMP2), 202311_s_at (COL1A1), 212464_s_at (FN1). HR: hazard ratio, CI: confidence interval.
Figure 4(A) Expression level of BGN in cancer and normal tissues. STAD: Stomach Adenocarcinoma; *P < 0.05. (B) The correlation analysis between BGN and ACAT1. BGN and ACAT1 are obviously positively correlated.
Figure 1The protein-protein interaction network of top 15 hub genes
Figure 2Top 3 modules from the protein-protein interaction network
(A) module 1, (B) the enriched pathways of module 1, (C) module 2, (D) the enriched pathways of module 2, (E) module 3, (F) the enriched pathways of module 3.